Gilead just lost one candidate, Bristol-Myers has licensed another; the race for non-alcoholic fatty liver disease drugs continues, as many companies eye its potential for a blockbuster drug.
Sequana Medical wants to embark on clinical trials in the U.S. for its implantable pump to treat complications from cirrhosis.
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
One company sees digital health as a way to do virtual liver biopsies
The color of your urine could be telling you something about your health condition. Yes, your standard yellow is where you want to be, but the different shades of the rainbow make an appearance on occasion. It’s not always scary when you’re pee is red, for example. Eating beets can result in beeturia—the passing of red or […]
Cold and flu season is emerging, and more than anything, you should just make sure to wash your hands regularly. But what if those germs are the least of your worries? Triclosan is an antimicrobial ingredient found in many soaps and toothpastes. Turns out, this can mess with liver fibrosis and tumors in mice when […]
An Indiana University spinout attracted investors from Johnson & Johnson Development Corp. and BioCrossroads with novel drugs to treat, and even potentially cure, patients with hepatitis B. Assembly Pharmaceuticals received an undisclosed amount for this seed round. This funding will finance the preclinical proof of concept and help the company establish its bio labs in San Francisco, […]
In an era of escalating healthcare costs and a growing preference for natural, holistic approaches to health, The Impact Brands emerges as a collective of diverse brands dedicated to supporting overall wellness through natural means.